Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: Final results of PRODIGE 23 phase III trial, a UNICANCER GI trial.

医学 卡培他滨 危险系数 临床终点 结直肠癌 奥沙利铂 新辅助治疗 内科学 相伴的 随机化 外科 癌症 随机对照试验 置信区间 乳腺癌
作者
Thierry Conroy,Najib Lamfichekh,Pierre-Luc Etienne,Emmanuel Rio,Éric François,Nathalie Mesgouez-Nebout,V. Vendrely,Xavier Artignan,Olivier Bouché,Dany Gargot,Valérie Boige,Nathalie Bonichon-Lamichhane,Christophe Louvet,Clotilde Morand,Christelle De La Fouchardière,Béata Juzyna,Éric Rullier,Frédéric Marchal,Florence Castan,Christophe Borg
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:38 (15_suppl): 4007-4007 被引量:162
标识
DOI:10.1200/jco.2020.38.15_suppl.4007
摘要

4007 Background: PRODIGE 23 investigated the role of neoadjuvant mFOLFIRINOX before preoperative (preop) chemoradiation (CRT), with TME-surgery and adjuvant chemotherapy (CT) in resectable locally advanced rectal cancer. Methods: PRODIGE 23 is a phase III multicenter randomized clinical trial. Eligible pts had cT3 or cT4, M0 rectal adenocarcinomas <15 cm from the anal verge, age 18-75 years, and WHO PS ≤1. Randomization was stratified by center, T stage, N status, tumor location, and perirectal fat extramural extension. Primary endpoint was 3-yr disease-free survival (DFS). Main secondary endpoints were ypT0N0 rate, overall survival (OS) and metastasis-free survival (MFS). 460 pts were required to observe 136 events to show a gain in 3-year DFS from 75% to 85% (HR=0.56) with a 2-sided α=0.05 and 90% power. HR and 95% CI were estimated by a stratified Cox proportional hazard model. Arm A pts received preop CRT (50 Gy, 2 Gy/fraction [fr]; 25 fr + capecitabine), surgery, then adjuvant CT for 6 months (mos). Arm B pts received 6 cycles of mFOLFIRINOX (oxaliplatin 85 mg/m², leucovorin 400 mg/m², irinotecan 180 mg/m² D1, and 5-FU 2.4 g/m² over 46 h) every 14 days, followed by the same preop CRT, surgery and 3 mos of adjuvant CT. Adjuvant CT consisted of mFOLFOX6 or capecitabine, depending on the centre’s choice for all pts. Imaging work-up, operative and pathology reports were centrally reviewed. Results: (ITT) Between 6/2012 and 6/2017, 230 and 231 pts were randomly assigned in Arm A/B, respectively by 35 participating centers. Pts characteristics were well balanced. Neoadjuvant mFOLFIRINOX and CRT in both arms were well tolerated. Compliance to CRT and to adjuvant CT was not hampered by neoadjuvant CT. Surgical morbidity did not differ between the 2 arms. The ypT0N0 rate was 11.7 vs 27.5% in Arm A/B (p<0.001). Median follow-up was 46.5 mos. 136 DFS events was reported. 3-yr DFS was significantly increased in arm B (HR 0.69, 95% CI 0.49-0.97, p=0.034): 68.5% (CI: 61.9-74.2) vs 75.7% (CI: 69.4-80.8) in arm A/B. The subgroup analysis showed no evidence of heterogeneity of the effect size of treatment on DFS. 3-yr MFS was also significantly higher in arm B: 71.7 in arm A vs 78.8% (HR 0.64, CI 0.44-0.93, p<0.02) in arm B. 3-yr OS was 87.7 vs 90.8% (HR 0.65, CI 0.40-1.05, p=0.077) in arm A/B, with 54.2% of the pts with recurrence being alive. Conclusions: Neoadjuvant mFOLFIRINOX plus CRT is safe, and significantly increased ypCR rate, DFS and MFS. OS data are not mature. Clinical trial information: NCT01804790 .

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
CodeCraft的应助被纯情的凡双采纳,获得10
刚刚
加油鸭子22对应助文件撤销了驳回
刚刚
業業发布了新的文献求助10
1秒前
Rain发布了新的文献求助10
2秒前
ws123完成签到,获得积分10
2秒前
2秒前
3秒前
3秒前
ercha完成签到,获得积分10
4秒前
随意完成签到,获得积分10
4秒前
拼搏的竹子的应助被qaz123采纳,获得50
4秒前
顾矜的应助被爱听歌的枫叶采纳,获得10
5秒前
科研通AI2S的应助被bjq采纳,获得10
5秒前
bjxm完成签到 ,获得积分10
6秒前
6秒前
6秒前
宋清华发布了新的文献求助10
6秒前
6秒前
深情安青的应助被锂离子采纳,获得10
6秒前
why完成签到,获得积分10
7秒前
南风喜欢发布了新的文献求助10
7秒前
7秒前
7秒前
乐空思的应助被chcmuer采纳,获得100
8秒前
慕青的应助被小珍采纳,获得10
8秒前
科研通AI6.2的应助被Chemisy1wang采纳,获得10
9秒前
宋清华发布了新的文献求助10
9秒前
gkam发布了新的文献求助10
9秒前
9秒前
李晨阳发布了新的文献求助10
10秒前
wg发布了新的文献求助10
10秒前
10秒前
小二郎的应助被Seorina采纳,获得10
10秒前
11秒前
爆米花的应助被时尚半仙采纳,获得10
11秒前
11秒前
羊正完成签到,获得积分10
12秒前
lkh发布了新的文献求助10
12秒前
小鹿完成签到,获得积分10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188013
求助须知:如何正确求助?哪些是违规求助? 9575913
关于积分的说明 21844012
捐赠科研通 7785789
什么是DOI,文献DOI怎么找? 3435148
关于科研通互助平台的介绍 2559521
邀请新用户注册赠送积分活动 2482051